These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Author: Fernández-Fernández L, Tejero E, Tieso A, Rabadán L, Munoz M, Santos I.
    Journal: Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805.
    Abstract:
    Pre-surgery serum levels of CA 72-4, CEA and CA 19-9 were quantified by the enzyme immunoassay method in 167 patients with histological diagnosis of gastric adenocarcinoma and in 92 patients with an endoscopic diagnosis of benign gastric pathology. CA 72-4 showed a better correlation between its serum levels and the different clinical stages of the disease than CEA and CA 19-9. At the individual study of stages I-II, CA 72-4 proved positive in 36.9% of patients while CEA and CA 19-9 appeared positive in 10.8% and 8.6%, respectively. In the ROC curve, at a specificity of 95%, the sensitivities of CA 72-4, CEA and CA 19-9 were 59.8%, 21% and 26.3% respectively. The discriminatory capacity of the test (area under the ROC curve +/- SD) was 0.86 +/- 0.03 in the case of CA 72-4, 0.52 +/- 0.03 for CEA and 0.58 +/- 0.03 for CA 19-9. In conclusion, in our series and with regard to CEA and CA 19-9, CA 72-4 shows better sensitivity and discriminatory capacity. CEA and CA 19-9 do not provide significant benefits when combined with CA 72-4 due to the good results obtained with the later marker alone.
    [Abstract] [Full Text] [Related] [New Search]